Piramal Pharma Ltd.
ISIN: INE0DK501011 • Market Cap: ₹27,898 Cr
The 5-Pillar Quality Audit for Piramal Pharma Ltd.
Evaluated across Profitability, Financial Health, Historical Compounding, Valuation Safety, and Ownership Governance:
1. Profitability & Capital Efficiency
Weight: 25%Measures operating margins (11.0%), Return on Capital Employed (2.4%), and equity compounding (—).
2. Financial Health & Solvency
Weight: 25%Debt-to-Equity is 0.68 with comfortable interest coverage and clean working capital.
3. Growth & Compounding Track Record
Weight: 20%Historical 3Y Sales CAGR (4.0%) and 3Y PAT CAGR (—).
4. Valuation Multiple & Margin of Safety
Weight: 15%Trades at P/E of — vs PEG of — and Dividend Yield of —.
5. Ownership Quality & Governance
Weight: 15%Promoter holding stands at 34.8%, backed by 27.1% institutional ownership.
Key Fundamental Strengths
Deep Institutional Sponsorship (27.1%)
Mutual funds, domestic DIIs, and foreign FIIs hold 27.1%, providing strong governance scrutiny.
Consistent Market Standing (Large Cap)
Established player in the Healthcare sector with an overall fundamental quality score of 43/100.
Areas to Watch & Potential Risks
Subdued Capital Efficiency (ROCE: 2.4%)
A sub-12% ROCE suggests return on capital barely exceeds the company's weighted average cost of capital (WACC).
Topline Stagnation (3Y Sales CAGR: 4.0%)
Revenue growth has slowed below inflation rates, indicating cyclical demand slowdown or saturated core markets.
Quantitative Strategy Eligibility
Checking PPLPHARMA against established Indian wealth creation frameworks:
Coffee Can Investing Framework
Fails 10%+ revenue growth or 15%+ minimum capital return benchmark over historical periods.
Quality Factor Screener (High RoIC + Low Debt)
Scorecard of 43/100 or leverage profile sits below strict quality index hurdles.
GARP / Value-Growth Blend
Valuation multiple or return metrics require further cyclical pullback.
Healthcare Sector Peer Comparison
Compare PPLPHARMA directly against top industry peers by market capitalization:
| Company | 5-Pillar Score | Market Cap | P/E | ROCE | D/E | Scorecard |
|---|---|---|---|---|---|---|
| Piramal Pharma Ltd. (PPLPHARMA)Current | 43/100 | ₹27,898 Cr | — | 2.4% | 0.68 | — |
| Sun Pharmaceutical Industries Ltd. (SUNPHARMA) | 77/100 | ₹4.55 Lakh Cr | 37.65 | 20.4% | 0.05 | View |
| Divi's Laboratories Ltd. (DIVISLAB) | 73/100 | ₹2.26 Lakh Cr | 77.37 | 19.4% | 0.00 | View |
| Torrent Pharmaceuticals Ltd. (TORNTPHARM) | 64/100 | ₹1.91 Lakh Cr | 87.43 | 9.5% | 1.76 | View |
| Apollo Hospitals Enterprise Ltd. (APOLLOHOSP) | 70/100 | ₹1.27 Lakh Cr | 60.55 | 19.1% | 0.62 | View |
| Cipla Ltd. (CIPLA) | 63/100 | ₹1.14 Lakh Cr | 33.94 | 16.1% | 0.01 | View |
Frequently Asked Questions: Piramal Pharma Ltd.
Q:What is the 5-Pillar Fundamental Score for Piramal Pharma Ltd. (PPLPHARMA)?
Piramal Pharma Ltd. has a RupeeTools Fundamental Score of 43/100, placing it in the 'Caution / Risky' category. Its pillar scores are: Profitability (37/100), Financial Health (60/100), Growth (40/100), Valuation (15/100), and Ownership Quality (60/100).
Q:Is PPLPHARMA fundamentally strong for long-term investment?
PPLPHARMA currently holds a moderate quality rating of 43/100. While it operates in the Healthcare sector, investors should monitor its profit margins before initiating long-term positions.
Q:Does PPLPHARMA pass the Coffee Can Investing filter?
No. PPLPHARMA does not currently meet the strict 15% ROCE and 10% sustained topline compounding threshold mandated by the Coffee Can investing framework.
Q:How does PPLPHARMA compare against other Healthcare peers?
Within India's Healthcare sector, PPLPHARMA trades at a P/E of — and generates an ROCE of 2.4%. Compare its 5-Pillar score of 43/100 against top sector peers like Sun Pharmaceutical Industries Ltd. (77/100), Divi's Laboratories Ltd. (73/100).
Regulatory & SEBI Research Analyst Compliance Disclaimer:
This 5-pillar fundamental score is an automated quantitative health check generated purely from historical public financial statements, corporate filings, and exchange disclosures for educational and informational purposes only. It does NOT constitute investment advice, a stock recommendation, or a solicitation to buy or sell securities. RupeeTools is not a SEBI-registered Research Analyst. Please consult a SEBI-registered financial advisor before making investment decisions.